Yuling Luo

Yuling Luo's Company

Yuling Luo is the Founder, Chairman, and CEO of Advanced Cell Diagnostics (ACD), a company he led from concept to successful product launch and commercialization. ACD is renowned for its breakthrough molecular detection technology, RNAscope, which has revolutionized the field of spatial biology and become the gold standard in RNA tissue imaging. His leadership has positioned ACD as a trailblazer in the life sciences sector, driving innovations in molecular pathology and diagnostic technology.

Yuling Luo's Title

Yuling Luo holds the prestigious roles of Founder, Chairman, and CEO at Advanced Cell Diagnostics (ACD). His extensive expertise and visionary leadership have been instrumental in steering the company towards groundbreaking advancements in RNA-based diagnostics. In addition to his executive roles at ACD, Luo has also served as a Venture Partner at Illumina Ventures, leveraging his deep knowledge of life sciences to guide investment strategies and foster innovation in the genomics sector.

Yuling Luo's Education and Expertise

Yuling Luo's educational background is rooted in the fields of chemistry and biochemistry. He received his B.S. in Chemistry from the University of Science & Technology of China, followed by a Ph.D. in Biochemistry from Case Western Reserve University. His expertise spans molecular detection technologies, functional genomics, and biochemistry, making him a leading figure in the development of innovative diagnostic tools and therapeutic targets. Luo's prolific research contributions have been published in numerous top-tier peer-reviewed journals, and his inventions have resulted in over 30 issued patents.

Yuling Luo's Achievements

Yuling Luo's career is marked by a series of significant achievements in the life sciences industry. He is the inventor of RNAscope, a revolutionary molecular detection technology that has set new standards in RNA tissue imaging. Luo co-founded Panomics, which was later acquired by Affymetrix in 2008, and played a pivotal role at Exelixis as a senior scientist. He also co-founded Avida Biomed, which was acquired by Agilent in 2022, demonstrating his ability to build and scale successful biotech companies. His leadership, innovation, and scientific contributions have earned him a distinguished reputation in the field.

Yuling Luo's Background

Yuling Luo is an innovator and serial entrepreneur with a rich background in the life sciences industry. Over his career, he has founded and led multiple successful startups, including Advanced Cell Diagnostics (ACD) and Avida Biomed. Luo's early career includes significant roles such as Vice President of Functional Genomics and Chief Scientific Officer at Panomics, and as a senior scientist at Exelixis, where he led teams in identifying and validating novel therapeutic targets. His relentless pursuit of innovation has made substantial impacts on molecular diagnostics and therapeutic development.